Oxaliplatin
Brand Names: Oxaliplatin Generic
Methodology & AI Transparency ⓘ
Oxaliplatin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: ; adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- 2 Real-world patient consensus: 86% patient "Worth It" rating across 16 anonymous logs for Oxaliplatin (RxNorm 1736776).
- 3 Typical cash cost range: Dispensing cost comparison spans $145.39 mail/discount cash up to $356.21 uninsured retail (federal NADAC $3.3800).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Oxaliplatin include nausea (12.6%), diarrhea (9.9%), fatigue (6.7%).
Ask our AI Specialists anything about Oxaliplatin
Oxaliplatin Mechanism, CYP450 Pathways & DailyMed Monograph
Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: ; adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ; treatment of advanced colorectal cancer. Oxaliplatin injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: ; adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) ; treatment of advanced colorectal cancer. ( 1 )
12.1 Mechanism of Action Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.
Systemic exposure to Oxaliplatin reflects Complete (~100%) parenteral systemic delivery for Oxaliplatin (5 mg/mL Injection, Solution) absorption kinetics and phase i/ii hepatic conjugation of oxaliplatin coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 3–12 hours terminal plasma half-life for Oxaliplatin half-life window (rapid intravascular/parenteral onset within 15–45 minutes after oxaliplatin administration response profile).
Dosing protocols (5 mg/mL Injection, Solution or 100 mg/20mL Injection, Solution or 100 mg/20mL Injection, Powder, Lyophilized, for Solution or 200 mg/40mL Injection, Solution or 5 mg/mL Injection, Solution, Concentrate) balance efficacy (86.00% patient satisfaction across 16 logs) against nausea (12.6% of reports), diarrhea (9.9% of reports), headache (6.9% of reports), with strict avoidance in oxaliplatin is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs.; reactions have included anaphylaxis .; history of hypersensitivity reaction to oxaliplatin or other platinum-based drugs..
Avoid overlapping platinum-based drug prescriptions alongside Oxaliplatin to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Oxaliplatin dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Oxaliplatin is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs.
- Reactions have included anaphylaxis .
- History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs.
Logged Side-Effect Incidence (16 Reports)
Oxaliplatin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Oxaliplatin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two: What a 301-Participant Study Found The POLAR clinical studies failed to meet their primary endpoint. JNCI cancer spectrum • 2022-11-01 • Phase III Randomized Trial | N = 301 | 93/100 | PMID 36308441 ↗ |
| Can This Approach Help? Inside the Latest Research on Ketotifen for Preventing Oxaliplatin-Induced Neuropathy in Stage III Colorectal This trial indicates that ketotifen may offer a promising approach for preventing OIPN. Journal of gastrointestinal cancer • 2026-05-07 • Phase III Randomized Trial | N = 32 | 88/100 | PMID 42096115 ↗ |
| New Insights on Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil,: What a 490-Participant Study Found The study failed to demonstrate clinical benefit of arfolitixorin (120 mg/m2) over leucovorin. Cancer research communications • 2024-01-04 • Phase III Randomized Trial | N = 490 | 87/100 | PMID 38059497 ↗ |
| New Insights on Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced: What a 250-Participant Study Found A total of 248 patients were eligible and included in analyses (median age, 66 [min-max, 24-84] years; 111 women [45%] and 137 men [55%]). JAMA surgery • 2026-05-01 • Phase III Randomized Trial | N = 250 | 87/100 | PMID 41779406 ↗ |
| New Insights on Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus: What a 583-Participant Study Found A total of 583 patients were enrolled; 293 were randomized to the SOX group and 290 were randomized to the FOLFOX group. JAMA network open • 2022-02-01 • Phase III Randomized Trial | N = 583 | 87/100 | PMID 35226081 ↗ |
Oxaliplatin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.3800/unit (~$101.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $356.21 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $145.39 / mo | View logs ↓ |
Oxaliplatin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Oxaliplatin RxNorm Concept ID | 1736776 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.3800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $356.21 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $145.39 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Oxaliplatin Patient Community, Cohort Filters & Dosage Logs
Deterministic Oxaliplatin reference combining NIH RxNorm (1736776), Medicaid NADAC ($3.3800/unit), and anonymous cohort outcomes (86% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Oxaliplatin community threads and patient logs by age, biological sex, dosage, and treatment duration.